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Use of the Epworth Sleepiness Scale to demonstrate 
response to treatment with nasal continuous positive 
airways pressure in patients with obstructive sleep 
apnoea 
F. M. HARDINGE*, D. J. PITSON AND J. R. STRADLING 
Osler Chest Unit, Churchill Hospital, Oxford, U.K. 
The Epworth Sleepiness Scale (ESS) was used to measure the degree of daytime sleepiness in two groups of 
patients with obstructive sleep apnoea (OSA), before and after treatment with nasal continuous positive air- 
ways pressure (CPAP). One group (50 patients) were assessed after 2 months CPAP treatment after which the 
mean ESS fell from 16.4 [standard error of mean (SEM) 0.521 to 7.0 (SEM 0,56). A second group (25 patients) 
were assessed after 1 yr of treatment: a similar fall in mean ESS was seen from 15.2 (SEM 1’ 13) before treatment 
to 6.0 (SEM 0.72). These results imply that the ESS can be used clinically to demonstrate the response of daytime 
sleepiness in OSA to treatment with CPAP, and that the fall in ESS seen after 2 months is sustained after 
1 yr of treatment. It is also possible that this approach could be used to monitor the progress of treatment 
with CPAP. 
__ 
Introduction 
Daytime sleepiness is the main presenting symp- 
tom of obstructive sleep apnoea (OSA), and also the 
principle indication for treatment with continuous 
positive airways pressure (CPAP) treatment. How- 
ever, measuring daytime sleepiness in an objective 
and clinically useful way has proved difficult. 
Although patients usually report great satisfaction 
with CPAP treatment in improving symptoms of 
daytime sleepiness, objective measurement and docu- 
mentation of this response is difficult. The Epworth 
Sleepiness Scale (ESS) is a questionnaire-derived 
scale of sleepiness which can be used to assess the 
degree of daytime sleepiness suffered by patients with 
OSA (1). Its use and reproducibility has been well 
validated in a variety of sleep conditions including 
OSA. This study used the ESS to monitor the 
response to CPAP in one group of patients with OSA 
after treatment for 2 months, and in a second group 
after treatment for 1 yr. 
Methods 
Seventy-five patients who had been referred 
consecutively by general practitioners and other 
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The first group of 50 patients (94% male; mean 
age 50.2 years) had a repeat ESS questionnaire 
administered at 2 months after commencing treat- 
ment with CPAP. Their mean weight was 110.1 kg, 
mean hypoxic dip rate was 21.5 (0, saturation falls 
of greater than 4% h - ‘), and mean CPAP pressure 
was 11.1 cm H,O. The second group of 25 patients 
(100% male; mean age 50.9 years) had a repeat 
questionnaire administered 1 yr after starting CPAP 
treatment. Their mean weight was 96.4 kg, mean 
0954-6111/95/090617+04 $12.0010 0 1995 W. B. Saunders Company Ltd 
physicians to an outpatient clinic specializing in sleep 
and breathing disorders were included in the study. 
All subjects were administered an ESS (Fig. 1) at 
their initial outpatient assessment. Obstructive sleep 
apnoea was diagnosed following an inpatient sleep 
study using the Visilab system (oximetry, pulse rate, 
body movements and snoring; Stowood Scientific 
Instruments, Oxford). Tracings were visually ana- 
lysed and data processed for the occurrence of 
repeated falls in oxygen saturation of greater than 
4% h - ‘. The diagnosis of OSA was made on the 
basis of clinical symptoms and the presence of 
obstructive apnoeas with oxygen desaturations. Con- 
tinuous positive airways pressure was then instituted 
at an individual pressure to suit each patient, deter- 
mined during a second overnight inpatient stay. 
Continuous positive airways pressure was titrated to 
abolish all obstructive apnoeas and snoring, and 
maintain a constant SaO, of greater than 90%. 
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Name: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Date: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Your age (years) . . . . . . . . . . . . . . . . . . . . . Your sex (Male = M/Female = F) . . . . . . . . . . . . . . . . . . . . . . 
How likely are you to doze off or fall asleep in the situations described in the box 
below, in contrast to feeling just tired? 
This refers to your usual way of life in recent times. 
Even if you haven’t done some of these things recently, try to work out how they 
would have affected you. 
Use the following scale to choose the most appropriate number for each 
situation:- 
0 = Would never doze 
1 = Sight chance of dozing 
2 = Moderate change of dozing 
3 = High change of dozing 
Situation Chance of dozing 
Sitting and reading 
Watching TV I I 
Sitting, inactive in a public place 
(e.g. a theatre or a meeting) 
As a passenger in a car for 1 hr without a break I / 
Lying down to rest in the afternoon when 
circumstances permit I I 
Sitting and talking to someone I i 
Sitting quietly after a lunch without alcohol I I 
In a car, while stopped for a few minutes in the traffic I I 
Thank you for your co-operation 
Fig. I The Epworth Sleepiness Scale. 
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Fig. 2 Epworth Sleepiness Scale results before and after treatment with CPAP. (a) For 2 months (n=50); (b) For 1 yr 
(n=25). Values plotted as mean with error bars indicating SEM. 
hypoxic dip rate was 22.9 (0, saturation falls of 
greater than 4% h - ‘), and mean CPAP pressure 
was 10.1 cm H,O. In this second group, compliance 
with treatment was assessed in 12 patients. These 12 
patients had Respironics CPAP machines with time 
clocks and were unaware that the clocks were being 
read to measure objective compliance. These were 
examined during routine yearly servicing of the 
equipment, and the total hours of use was noted so 
that the average duration that CPAP was used each 
night could be calculated. 
Mean and SEM of ESS scores were calculated 
for each group before and after treatment, and 
paired t-tests were performed (SAS suite of computer 
programmes, SAS Institute, Cary, N.C.). 
Results 
In the first group, there was a significant fall in 
mean ESS from 16.4 (SEM 0.52) before CPAP treat- 
ment to 7.0 (SEM 0.56) after 2 months treatment 
[P=O.OOOl, Fig. 2(a)]. A similar fall in mean ESS was 
seen in the second group, from 15.2 (SEM 1.13) before 
treatment to 6.0 (SEM 0.72) after treatment for 1 yr 
[P=O.OOOl, Fig. 2(b)]. In the 12 patients of this 
second group in whom compliance was assessed, 
mean average nightly use of CPAP was 6.5 (SEM 
0.52) h. 
Discussion 
The initial ESS of both groups of untreated 
patients with OSA were similar to scores obtained in 
previous studies by patients classified as suffering 
from ‘severe’ OSA (2,3). When treated with CPAP 
for 2 months, the ESS of the first group fell signifi- 
cantly almost into the normal range previously 
described for middle-aged non-snoring subjects (1). 
After CPAP for 1 yr, a reduction in ESS was 
observed down to a level usually seen in normal 
subjects, which has not been demonstrated in previ- 
ous studies examining the effect of CPAP for up to 9 
months (2,3). In this study, there was no eontrol 
group receiving either no treatment or a placebo 
treatment, because it was felt inappropriate to 
withhold active treatment over this length of time. 
Similarly, it was not possible to give ‘sham’ CPAP 
treatment because it would have been obvious to the 
patients’ partners that they were continuing to snore 
and have apnoeic spells. In addition, patients would 
have been very unlikely to comply with treatment 
unless they felt they were gaining benefit. Therefore, 
there is a possibility that some of the fall in ESS was 
due to a placebo effect, but compliance with treat- 
ment was good, and it is much more likely that the 
fall in ESS was due to an active effect of receiving 
CPAP treatment. Objective measurement of compli- 
ance levels in other studies have been somewhat 
lower at under 3.6 h night - ’ (4). 
Alternative questionnaires such as the Stanford 
Sleepiness Scale (5) have been used to measure 
daytime sleepiness, but actually measure feelings of 
tiredness as well as sleepiness. Other objective 
methods are the multiple sleep latency test (MSLT) 
and multiple unprepared reaction time test 
(MUPRT), but neither have proved to be clinically 
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useful. The MSLT has been the most widely used 
(measures speed of sleep onset four times across the 
day), but is very time-consuming to perform, unlike 
the ESS which is brief and self-administered. The 
MSLT also measures the ability of a subject to fall 
asleep, rather than true sleepiness (6), and there is 
considerable overlap with results of normal people 
(7). Only a very small, but significant, improvement 
after treatment with CPAP has been demonstrated 
compared to placebo (8), possibly reflecting that the 
MSLT is too sensitive a measure of clinically relevant 
sleepiness. The MUPRT is used to measure vigilance 
(measures reaction time in response to random visual 
stimuli) as this is an important component of:daytime 
performance (9). However, subjects can often uprate 
their performance for the period of the test, thus 
reducing the sensitivity of the results. Following 
treatment with CPAP, only a small non-significant 
improvement has been demonstrated (10). Thus, 
neither of these tests are particularly useful in clinical 
practice, and simple questionnaires such as the ESS 
seem to provide the best assessment of daytime 
sleepiness in OSA. It is possible that the ESS is 
measuring a different component of daytime sleepi- 
ness to the MSLT, and thus reflects more clearly the 
subjective impression gained when talking to 
patients. 
As well as demonstrating the response of daytime 
sleepiness in OSA to CPAP treatment, it is possible 
that the changes in the ESS could be used to monitor 
the progress of treatment: a rise in the ESS might 
indicate that CPAP was not as effective for some 
reason, such as machine failure or patient weight 
gain, and act as an early warning to restudy the 
patient. In the three patients who exhibited only a 
small fall in ESS following 2 months treatment with 
CPAP [Fig. 2(b)], all admitted to poor compliance; 
one patient because of poor nasal patency, one 
patient because of recent illness with tonsillitis, and 
the third patient because of claustrophobia when 
using the mask. This use of the ESS to monitor the 
effectiveness of CPAP treatment needs to be further 
evaluated. 
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